Presumably, this discrepancy results from the fact that BRCAPRO does not model any of the residual familial clustering of breast cancer, other than BRCA1 or BRCA2, so that individuals with moderate family histories are assigned probabilities for being mutation carriers that are too high. The gene discussed is BRCA1; the disease is breast carcinoma.